Neocor Therapeutics

Executive Summary

Neocor Therapeutics is a pre-clinical biotechnology company based in Lyon, France, dedicated to pioneering innovative therapies for heart regeneration and repair. Founded in 2019, the company focuses on addressing the significant unmet medical need in cardiac care, particularly for conditions like heart failure where current treatments are limited. By leveraging novel therapeutic approaches, Neocor aims to unlock the heart's regenerative potential, offering hope for patients with cardiac damage. Although still in early stages, the company's mission aligns with a growing field of cardiac regenerative medicine, and its progress could be transformative if successful. Key upcoming milestones include advancing lead candidates through preclinical studies and securing partnerships or funding to support IND-enabling work.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Animal Models40% success
• Q2 2027Series A Funding Round Announcement50% success
• Q1 2027Partnership with Academic or Industrial Collaborator30% success